Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCAPE study of capecitabine pharmacokinetics in CES1 variant carriers
NL-OMON59899Phase 4Recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of capecitabine in abdominal malignancy (2 arms), sponsored by Erasmus MC. Primary endpoint: Difference in 5-FU exposure on cycle 1 day 14. Started Jan 2025; status: recruiting.
02
Drugs
capecitabine
03
Conditions
abdominal malignancy
Beyond the preview
Go deeper on NL-OMON59899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59899.